Sign in →

Test Code LABTPC5AB Terminal Activation Pathway

Clinical Information

Complement biomarker SC5b-9 is part of the Terminal Complement Activation Pathway and is used to monitor patients with suspected Thrombotic Microangiopathies (TMA) and atypical hemolytic uremic syndrome (aHUS).

Synonym

  • TPC5AB
  • SC5b-9 Complement
  • Membrane attack complex (MAC)
  • Terminal complement complex (TCC)

Specimen Required

Acceptable Container/Tube: EDTA lavender top tube
Specimen Volume: 0.5 mL plasma
Specimen Minimum Volume: 0.5 mL plasma
Processing instructions: Within 3 hours of collection, process into plasma. Centrifuge for 15 minutes at 1500 g. Transfer plasma to plastic tube. FREEZE IMMEDIATELY at -70°C or below. Ship frozen on dry ice.

Specimen Stability Information

Ambient: Whole blood must be processed into plasma and frozen within 3 hours from collection.

Frozen: 4 weeks at -70°C or below

Rejected Due To

  • Clotted specimens

Reference Values

6-598 ng/mL

Cautions

Measure of SC5b-9 complement should be ideally performed prior to treatment initiation and in the absence of therapy with complement inhibitors, such as eculizumab and ravulizumab. Complement inhibitors may affect the performance or results of this assay.

Method Description

Quidel enzyme-linked immunosorbent assay (ELISA) 

Performing Lab

Clinical Lab UH

Day(s) Performed

Monday through Friday (excludes OSU holidays)

Report Available

6 to 8 days

Reporting Name

Terminal Activation Pathway

CPT Code Information

86160

LOINC Code Information

13117-7